Publications by authors named "Michaela Mattheus"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

29,352

Total Likes

1,730

Extended Reach

1,250,642

Social Features

141
E
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman

July 2016

Videos about Article: user user

2 1 22 8 29

View All Article and Social Media Activity
E
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle

November 2015

Videos about Article: user user user 2

5 2 42 131 23 76 2

View All Article and Social Media Activity
E
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.
Francesco Fioretti, Javed Butler, Jacob A Udell, W Schuyler Jones, Mark C Petrie, Michaela Mattheus

ESC Heart Fail· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction.
Rahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, Stefan D Anker, Josephine Harrington, Michaela Mattheus

Nat Cardiovasc Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.
Mark C Petrie, Jacob A Udell, Stefan D Anker, Josephine Harrington, W Schuyler Jones, Michaela Mattheus

Eur J Heart Fail· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.
Christoph Wanner, Masaomi Nangaku, Bettina J Kraus, Bernard Zinman, Michaela Mattheus

Nephrol Dial Transplant· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium.
Björn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, Frederik Collin, Annett Keller, Michaela Mattheus

Ther Innov Regul Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial.
David Fitchett, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Stefan D Anker, Michaela Mattheus

Cardiovasc Diabetol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study.
Robert J Massey, Yu Chen, Marina Panova-Noeva, Michaela Mattheus, Moneeza K Siddiqui

Cardiovasc Diabetol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
Jacob A Udell, Mark C Petrie, W Schuyler Jones, Stefan D Anker, Josephine Harrington, Michaela Mattheus

J Am Coll Cardiol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial.
Silvio E Inzucchi, Christoph Wanner, David Fitchett, Bernard Zinman, Stefan D Anker, Michaela Mattheus

Diabetes Res Clin Pract· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
Adrian F Hernandez, Jacob A Udell, W Schuyler Jones, Stefan D Anker, Mark C Petrie, Michaela Mattheus

Circulation· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease.
Abhinav Sharma, Silvio E Inzucchi, Jeffrey M Testani, Anne Pernille Ofstad, David Fitchett, Michaela Mattheus

ESC Heart Fail· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
Tripti Rastogi, João Pedro Ferreira, Javed Butler, Bettina Johanna Kraus, Michaela Mattheus

Eur J Heart Fail· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin after Acute Myocardial Infarction.
Javed Butler, W Schuyler Jones, Jacob A Udell, Stefan D Anker, Mark C Petrie, Michaela Mattheus

N Engl J Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
Samy Hadjadj, Mark E Cooper, Dominik Steubl, Michaela Petrini, Stefan Hantel, Michaela Mattheus

Kidney Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Nikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, Odd Erik Johansen, Mark E Cooper, Michaela Mattheus

JAMA Cardiol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.
Robert Weingold, Bernard Zinman, Michaela Mattheus, Anne Pernille Ofstad, Dominik Steubl

J Diabetes Complications· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.
Subodh Verma, Andrew Kosmopoulos, Deepak L Bhatt, David Fitchett, Anne Pernille Ofstad, Michaela Mattheus

Am J Prev Cardiol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.
Bernhard K Krämer, Sibylle J Hauske, Robert Chilton, Johannes F E Mann, Lars Gullestad, Michaela Mattheus

J Diabetes Complications· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials.
Priyadarshini Balasubramanian, Walter N Kernan, Kevin N Sheth, Anne Pernille Ofstad, Julio Rosenstock, Michaela Mattheus

Stroke· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
Julio Rosenstock, Ahmed A Kolkailah, Darren K McGuire, Mark A Espeland, Michaela Mattheus

Diabetes Obes Metab· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
Moahad S Dar, Christoph Wanner, Nikolaus Marx, Anne Pernille Ofstad, Michaela Mattheus

Diabetes Obes Metab· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Faiez Zannad, João Pedro Ferreira, John Gregson, Bettina Johanna Kraus, Michaela Mattheus

Eur J Heart Fail· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kohei Kaku, Christoph Wanner, Stefan D Anker, Stuart Pocock, Atsutaka Yasui, Michaela Mattheus

Diabetes Obes Metab· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
João Pedro Ferreira, Silvio E Inzucchi, Michaela Mattheus, Thomas Meinicke, Dominik Steubl

Diabetes Obes Metab· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.
Piero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus

EClinicalMedicine· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis